Medical

Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June 13, 2022 in an article in Nature's Scientific Reports titled "Intranasal Immunization with a Proteosome-Adjuvanted … [Read more...] about Oragenics says preclinical data support further development of its intranasal COVID-19 vaccine

Optinose has announced that the Phase 3 ReOpen2 trial of Xhance fluticasone propionate nasal spray (OPN-375) in patients with chronic sinusitis without nasal polyps demonstrated significant improvement compared to placebo in both patient reported symptoms at week 4 and inflammation measured by CT scan at week 24. The FDA approved Xhance in 2017 for the treatment of … [Read more...] about Phase 3 ReOpen2 trial of Optinose’s Xhance intranasal fluticasone meets primary endpoints

Tiziana Life Sciences has announced that a second multiple sclerosis patient who received the company's intranasal foralumab for three months as part of an expanded access program at Brigham and Women’s Hospital (BWH) has showed significant improvement.  According to Tiziana, PET imaging demonstrated inhibition of microglial activation, and the patient also showed … [Read more...] about Tiziana reports positive results for intranasal foralumab in second MS patient

Following an advice meeting with the Paul Erhlich Institute, Israeli biopharm company BiondVax Pharmaceuticals announced plans for development of its lead candidate, an inhaled COVID-19 nanosized antibody (NanoAb) therapy. The company said that it hopes to initiate a Phase 1/2a clinical trial of the inhaled NanoAb in COVID-19 patients in 2023, following completion of … [Read more...] about BiondVax announces development plans for inhaled NanoAb for COVID-19

SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary function. The study enrolled 57 healthy volunteers who got either SIS or placebo delivered via jet nebulizer 4 times per day for 5 days, with … [Read more...] about SoftOx reports positive Phase 1 results for its hypochlorous acid inhalation solution

Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the initiation of the Phase 1 trial in November 2021. The company previously announced data from pre-clinical studies showing that Neumifil has … [Read more...] about Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray

According to Opiant Pharmaceuticals, a pharmacodynamic study of the company's OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg of naloxone in reversing respiratory depression caused by a synthetic opioid at 5 minutes post dose. OPNT003, which is … [Read more...] about PD study of Opiant’s intranasal nalmefene meets primary endpoint